Harrow (HROW) Expected to Announce Earnings on Monday
by Doug Wharley · The Cerbat GemHarrow (NASDAQ:HROW – Get Free Report) is expected to be announcing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Harrow to post earnings of ($0.3538) per share and revenue of $52.4260 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.
Harrow Stock Down 2.7%
Shares of Harrow stock traded down $1.10 on Monday, hitting $39.80. 244,413 shares of the company traded hands, compared to its average volume of 674,076. Harrow has a 12-month low of $21.12 and a 12-month high of $54.85. The company has a quick ratio of 2.06, a current ratio of 2.20 and a debt-to-equity ratio of 4.67. The company has a market cap of $1.48 billion, a PE ratio of -234.10 and a beta of 0.34. The company has a 50-day moving average price of $39.16 and a 200 day moving average price of $42.43.
Hedge Funds Weigh In On Harrow
Several institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company raised its stake in shares of Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock valued at $505,000 after acquiring an additional 341 shares in the last quarter. Captrust Financial Advisors grew its holdings in Harrow by 0.5% during the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock valued at $3,428,000 after purchasing an additional 376 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Harrow by 1.7% in the third quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock valued at $1,422,000 after purchasing an additional 500 shares during the period. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Harrow in the fourth quarter worth $26,000. Finally, Cetera Investment Advisers lifted its stake in shares of Harrow by 2.6% in the fourth quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock worth $1,140,000 after buying an additional 597 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts have commented on HROW shares. Nomura downgraded Harrow to a “neutral” rating in a research note on Wednesday, March 18th. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Weiss Ratings lowered Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Cantor Fitzgerald lowered their price target on Harrow from $94.00 to $91.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Finally, Zacks Research upgraded Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $69.86.
View Our Latest Analysis on Harrow
Harrow Company Profile
Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.
Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.